Raymond James Financial Services Advisors, Inc. Ligand Pharmaceuticals Inc Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$0.01 - $107.56 $23 - $250,077	2,325 New	2,325 $200,000
Q3 2019 Nov 07, 2019	SELL	$86.25 - $120.16 $224,422 - $312,656	-2,602 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$107.38 - $129.34 $54,871 - $66,092	511 Added 24.44%	2,602 $297,000
Q1 2019 May 06, 2019	BUY	$105.93 - $142.47 $221,499 - $297,904	2,091 New	2,091 $263,000
Q4 2018 Feb 11, 2019	SELL	$128.36 - $272.13 $166,097 - $352,136	-1,294 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $94,608 - $122,971	-448 Reduced 25.72%	1,294 $355,000
Q2 2018 Jul 30, 2018	BUY	$150.77 - $207.98 $53,975 - $74,456	358 Added 25.87%	1,742 $361,000
Q1 2018 Apr 16, 2018	BUY	$138.63 - $182.62 $191,863 - $252,746	1,384 New	1,384 $229,000

Others Institutions Holding LGND

# of Institutions

257

Shares Held

18.2M

Call Options Held

26.8K

Put Options Held

9.3K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.88B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account